Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 17/20 | 0.67 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019417 | 0.91 | PTGIR (0.64) | PTGIRPTGDRMGLLCHRM3 | |
| SCHEMBL29019402 | 0.91 | PTGIR (0.64) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019404 | 0.91 | PTGIR (0.64) | PTGIRPTGDRMGLLCHRM3 | |
| SCHEMBL29019383 | 0.90 | PTGIR (0.59) | PTGIRPTGDRMGLLCHRM3PTGER4 | |
| SCHEMBL29019412 | 0.89 | PTGIR (0.73) | PTGIRPTGDRMGLLCHRM3PTGER4 | |
| SCHEMBL29019375 | 0.88 | PTGIR (0.69) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019411 | 0.88 | PTGIR (0.62) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL23851382 | 0.87 | PTGIR (0.68) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL29019408 | 0.87 | PTGIR (0.68) | PTGIRPTGDRMGLLPTGER4PTGER3 | |
| SCHEMBL23853931 | 0.86 | PTGIR (0.73) | PTGIRPTGDRCHRM3PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003123-B | Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders | 艾尼纳制药公司 | 2023-06-23 | — | — | CN | disclosed |